Hideki Mitsui

TL;DR: The results suggest that, although the mechanisms underlying constitutive activation of KITG559 or KITV814 may be different, both of the activating mutations have a function to induce a factor-independent and tumorigenic phenotype and raise the possibility that the constitutively activating mutations of c-kit may play a causal role in development of hematologic malignancies.

TL;DR: It was found that mast cells developed by c-kit ligand were immature even after culture for 14 weeks, and could be sensitized with human IgE for anti-IgE-induced release of histamine, prostaglandin D2, and leukotriene C4.

TL;DR: It is suggested that IL-3, Il-4, IL-5, and IL-6, which are mainly produced by T-helper 2 lymphocytes, might regulate the functions of human mast cells in vivo via specific receptors in allergic reactions.

TL;DR: In vivo administration of CBD-CS1 fragment into mice was found to increase the numbers of hematopoietic progenitor cells in bone marrow and spleen in a dose-dependent manner, suggesting that FN may function on hematopsic stem/progenitor cells as a growth-supporting factor in vitro and in vivo.

TL;DR: The findings suggest that CML patients who meet all the eligibility criteria that have commonly been used in the TFR trials are able to discontinue imatinib use safely, and TFR may be valuable as a new goal for CML treatment in Japan.